Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Citius Pharmaceuticals Reports Expected Milestones

Author: Benzinga Newsdesk | July 10, 2024 09:11am

Multiple catalysts for potentially transformative assets in second half of 2024
Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approved
First-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantage
Financial platform and pending oncology spin-off support pipeline development and investment in long-term growth
Clinical and operational achievements offer powerful levers for value creation
National Sales Director onboarded to recruit and lead the sales organization in preparation for anticipated launch of LYMPHIR

Posted In: CTXR